Sphera Funds Management LTD. Trims Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)

Sphera Funds Management LTD. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 79.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the biopharmaceutical company’s stock after selling 155,232 shares during the quarter. Sphera Funds Management LTD.’s holdings in Alnylam Pharmaceuticals were worth $3,501,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ALNY. Principal Financial Group Inc. boosted its stake in Alnylam Pharmaceuticals by 5.4% in the 1st quarter. Principal Financial Group Inc. now owns 24,525 shares of the biopharmaceutical company’s stock worth $2,921,000 after purchasing an additional 1,263 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 271,295 shares of the biopharmaceutical company’s stock worth $26,720,000 after purchasing an additional 16,110 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Alnylam Pharmaceuticals by 66.6% in the 2nd quarter. Wells Fargo & Company MN now owns 196,803 shares of the biopharmaceutical company’s stock worth $19,383,000 after purchasing an additional 78,675 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in Alnylam Pharmaceuticals by 33.9% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 36,200 shares of the biopharmaceutical company’s stock worth $3,565,000 after purchasing an additional 9,164 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its stake in Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. State of Wisconsin Investment Board now owns 79,532 shares of the biopharmaceutical company’s stock worth $7,833,000 after purchasing an additional 1,416 shares in the last quarter. Institutional investors own 88.46% of the company’s stock.

NASDAQ:ALNY opened at $74.38 on Friday. The company has a quick ratio of 10.96, a current ratio of 11.05 and a debt-to-equity ratio of 0.02. The company has a market cap of $8.06 billion, a PE ratio of -13.72 and a beta of 2.54. Alnylam Pharmaceuticals, Inc. has a 1-year low of $63.57 and a 1-year high of $153.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($0.41). The firm had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $22.66 million. Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. Alnylam Pharmaceuticals’s revenue for the quarter was down 87.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.34) earnings per share. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.75 earnings per share for the current fiscal year.

Several analysts have commented on ALNY shares. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. BidaskClub cut shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 24th. Leerink Swann started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 27th. They set a “market perform” rating and a $63.00 price objective for the company. ValuEngine cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 21st. Finally, BMO Capital Markets restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 18th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $138.44.

TRADEMARK VIOLATION WARNING: “Sphera Funds Management LTD. Trims Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.wkrb13.com/2018/12/08/sphera-funds-management-ltd-trims-holdings-in-alnylam-pharmaceuticals-inc-alny.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Featured Story: 52-Week High/Low

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply